Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntercede Regulatory News (IGP)

Share Price Information for Intercede (IGP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 105.00
Bid: 102.00
Ask: 108.00
Change: 1.00 (0.96%)
Spread: 6.00 (5.882%)
Open: 104.00
High: 105.00
Low: 104.00
Prev. Close: 104.00
IGP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Conversion of Loan Notes

1 Jun 2009 07:00

RNS Number : 0789T
Intercede Group PLC
01 June 2009
 



1 JUNE 2009

Intercede Group plc

("Intercede" or the "Company")

Conversion of Loan Notes

 

 

Intercede Group plis pleased to announce that it has received notification from the remaining holders of the convertible loan notes issued by the Company on 31 March 2000 and 6 December 2001 ("the Loan Notes") that they have elected to convert the Loan Notes (together with associated interest for the period to 31 May 2009) into ordinary shares of 1p each in the Company. In order to effect the conversion, the Company has issued 3,877,166 new ordinary shares at a price of 15.0p per share and 6,897,083 new ordinary shares at a price of 20.0p per Ordinary Share (together "New Shares"). Following such conversion, the total issued share capital of the Company will be 48,178,005 ordinary shares of 1p each.

 

Application will be made to the London Stock Exchange for the New Shares to be admitted to trading on AIM. The New Shares will rank pari passu in all respects with the existing Ordinary Shares in issue and it is expected that trading will commence in the New Shares on 5 June 2009

Richard Parris, Chairman and Chief Executive of Intercede, commented:

"We are delighted with the confidence shown in Intercede by the convertible loan note holders in converting all of the Loan Notes into equity. The conversion significantly strengthens the Company's balance sheet and leaves Intercede with a substantial cash balance as it continues to enjoy commercial success. This success, especially in the last year, provides grounds for all shareholders to be optimistic."

Intercede will issue its Preliminary Results for the year ended 31 March 2009 by mid June 2009.

ENQUIRIES

 

Intercede Group plc

Tel. +44 (0)1455 558111

Richard Parris, Chairman & Chief Executive

Andrew Walker, Finance Director

FinnCap

Tel. +44 (0)20 7600 1658

Clive Carver

Pelham Public Relations

Archie Berens

Tel. +44 (0)20 7337 1509

About Intercede

 

Intercede is the producer of the MyID® Identity and Credential Management System (IDCMS). Intercede's MyID is the only IDCMS software product that enables organizations to easily and securely manage the identities of people and their associated identity credentials within a single, integrated, workflow driven platform. This includes enabling and managing: secure registration, biometric capture, application vetting and approval through to smart card personalization, issuance and management.

Intercede's MyID is being used around the world by large corporations, governments and banks to manage millions of identities for employees, citizens and customers. Notable deployments in the US include 10 Federal Agencies, a programme with Lockheed Martin and two major US financial institutions. In Europe and the Middle East, Intercede's MyID is being deployed in support of government identity, health and corporate employee ID security projects.

Intercede and MyID are registered trademarks or trademarks in the UK, US and/or other countries. For more information visit http://www.intercede.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCSEFFMUSUSESI
Date   Source Headline
26th Apr 202410:02 amRNSShare Incentive Scheme
23rd Apr 20247:00 amRNSCapital Markets Day
8th Apr 20247:00 amRNSTrading Update
2nd Apr 20247:00 amRNSContract and Subscription Renewals
25th Mar 20243:38 pmRNSHolding(s) in Company
25th Mar 20243:35 pmRNSHolding(s) in Company
22nd Mar 20247:00 amRNSNew Orders and Trading Update
21st Mar 20247:00 amRNSNew Product Announcement: Launch of MyID MFA v5
6th Feb 20247:00 amRNSDirector/PDMR Shareholding
29th Jan 20247:00 amRNSNew Orders
18th Jan 20249:55 amRNSDirector/PDMR Shareholding
3rd Jan 20247:00 amRNSMajor New Contract Win
7th Dec 20237:00 amRNSUpdate on Major New Contract Win
5th Dec 202312:30 pmRNSMajor New Contract with Large US Federal Agency
22nd Nov 20237:00 amRNSDirector/PDMR Shareholding
21st Nov 20237:01 amRNSNew Contract and Renewal Orders
21st Nov 20237:00 amRNSHalf-year Report
7th Nov 20237:00 amRNSContract and Renewals Orders
25th Oct 20234:44 pmRNSDirector/PDMR Shareholding
24th Oct 20237:00 amRNSNotice of Interim Results & Investor Presentation
20th Oct 20237:03 amRNSAppointment of Non-Executive Director
11th Oct 20237:00 amRNSDirector/PDMR Shareholding
10th Oct 20237:00 amRNSTrading Update
21st Sep 20231:31 pmRNSResult of AGM
4th Sep 20237:00 amRNSContract and Renewals Orders
30th Aug 20237:10 amRNSNotice of AGM and Publication of Annual Report
20th Jun 20237:01 amRNSBoard Changes
20th Jun 20237:00 amRNSFinal Results
12th Jun 20237:00 amRNSNotice of Results & Investor Presentation
27th Apr 20237:00 amRNSShare Incentive Plan
17th Apr 20237:00 amRNSTrading Update
3rd Apr 20237:00 amRNSContract wins/renewals
3rd Feb 202310:46 amRNSDirector/PDMR Shareholding
31st Jan 20237:00 amRNSChange of Auditors
23rd Jan 20234:40 pmRNSSecond Price Monitoring Extn
23rd Jan 20234:35 pmRNSPrice Monitoring Extension
23rd Jan 20232:05 pmRNSSecond Price Monitoring Extn
23rd Jan 20232:00 pmRNSPrice Monitoring Extension
23rd Jan 20237:00 amRNSTrading Update
11th Jan 20232:30 pmRNSDirector/PDMR Shareholding
2nd Dec 20228:45 amRNSDirector/PDMR Shareholding
22nd Nov 20227:00 amRNSHalf-year Report
11th Nov 20227:00 amRNSNotice of Interim Results & Investor Presentation
13th Oct 202210:30 amRNSDirector/PDMR Shareholding
11th Oct 20221:00 pmRNSDirector/PDMR Shareholding
10th Oct 20228:00 amRNSLong Term Incentive Plan
10th Oct 20227:01 amRNSAcquisition of Authlogics Ltd
10th Oct 20227:00 amRNSTrading Update
28th Sep 202212:22 pmRNSResult of AGM
15th Sep 20227:00 amRNSDirector/PDMR Shareholding and Issue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.